ID

29229

Description

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00789191

Link

https://clinicaltrials.gov/show/NCT00789191

Keywords

Versions (1)
  1. 3/10/18 3/10/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

March 10, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes NCT00789191

English

Eligibility Diabetes NCT00789191

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00789191
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with type 2 diabetes for at least 6 months before trial start
Description

Non-Insulin-Dependent Diabetes Mellitus Disease length

Data type

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
treatment with at least 1000 mg metformin per day for at least 3 months
Description

Metformin U/day

Data type

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0456683
insulin-naive (short-term insulin treatment of up to 14 days is allowed)
Description

Insulin naive | Insulin short-term allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0919936
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0443303
UMLS CUI [2,3]
C0683607
dpp-4 (dipeptidyl peptidase-4) inhibitor naive
Description

Dipeptidyl Peptidase-4 Inhibitor naive

Data type

boolean

Alias
UMLS CUI [1,1]
C3537225
UMLS CUI [1,2]
C0919936
hba1c (glycosylated haemoglobin a1c) between 7.5-10.0% by central laboratory analysis
Description

Glucohemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0202054
bmi (body mass index) lesser than or equal to 45.0 kg/m2
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
able and willing to take one subcutaneous injection every day
Description

Subcutaneous Injections Quantity per day Able | Subcutaneous Injections Quantity per day Willing

Data type

boolean

Alias
UMLS CUI [1,1]
C0021499
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0439505
UMLS CUI [1,4]
C0085732
UMLS CUI [2,1]
C0021499
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0439505
UMLS CUI [2,4]
C0600109
able and willing to perform mandatory smpg (self measured plasma glucose) measurements
Description

Plasma Glucose Measurement Self Able | Plasma Glucose Measurement Self Willing

Data type

boolean

Alias
UMLS CUI [1,1]
C0202042
UMLS CUI [1,2]
C0036588
UMLS CUI [1,3]
C0085732
UMLS CUI [2,1]
C0202042
UMLS CUI [2,2]
C0036588
UMLS CUI [2,3]
C0600109
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known or suspected allergy or intolerance to any of the trial products or related products
Description

Hypersensitivity Investigational New Drugs | Hypersensitivity Suspected Investigational New Drugs | Intolerance to Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Related | Hypersensitivity Suspected Pharmaceutical Preparations Related | Intolerance to Pharmaceutical Preparations Related

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0750491
UMLS CUI [2,3]
C0013230
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C0013230
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0013227
UMLS CUI [4,3]
C0439849
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C0750491
UMLS CUI [5,3]
C0013227
UMLS CUI [5,4]
C0439849
UMLS CUI [6,1]
C1744706
UMLS CUI [6,2]
C0013227
UMLS CUI [6,3]
C0439849
severe hypertension
Description

Hypertension, severe

Data type

boolean

Alias
UMLS CUI [1]
C4013784
treatment with thiazolidinedione (tzd) or glp-1 (glucagon-like peptide-1) analogues within 2 months prior to trial start
Description

Thiazolidinediones | GLP-1 Mimetics

Data type

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C3273809
cardiac disease, within the last 12 months
Description

Heart Disease

Data type

boolean

Alias
UMLS CUI [1]
C0018799
impaired hepatic function
Description

Liver Dysfunction

Data type

boolean

Alias
UMLS CUI [1]
C0086565
impaired renal function
Description

Renal Insufficiency

Data type

boolean

Alias
UMLS CUI [1]
C1565489
proliferative retinopathy or macular oedema requiring acute treatment
Description

Proliferative retinopathy Treatment required for | Macular retinal edema Treatment required for

Data type

boolean

Alias
UMLS CUI [1,1]
C0339467
UMLS CUI [1,2]
C0332121
UMLS CUI [2,1]
C0271051
UMLS CUI [2,2]
C0332121
female of childbearing potential
Description

Childbearing Potential

Data type

boolean

Alias
UMLS CUI [1]
C3831118
known or suspected abuse of alcohol, narcotics or illicit substances
Description

Alcohol abuse | Narcotic Abuse | DRUG ABUSE ILLICIT | Alcohol abuse Suspected | Narcotic Abuse Suspected | DRUG ABUSE ILLICIT Suspected

Data type

boolean

Alias
UMLS CUI [1]
C0085762
UMLS CUI [2]
C0524661
UMLS CUI [3]
C0743253
UMLS CUI [4,1]
C0085762
UMLS CUI [4,2]
C0750491
UMLS CUI [5,1]
C0524661
UMLS CUI [5,2]
C0750491
UMLS CUI [6,1]
C0743253
UMLS CUI [6,2]
C0750491
Back to the top of the page

Similar models

Eligibility Diabetes NCT00789191

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00789191
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
diagnosed with type 2 diabetes for at least 6 months before trial start
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Metformin U/day
Item
treatment with at least 1000 mg metformin per day for at least 3 months
boolean
C0025598 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
Insulin naive | Insulin short-term allowed
Item
insulin-naive (short-term insulin treatment of up to 14 days is allowed)
boolean
C0021641 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0021641 (UMLS CUI [2,1])
C0443303 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
Dipeptidyl Peptidase-4 Inhibitor naive
Item
dpp-4 (dipeptidyl peptidase-4) inhibitor naive
boolean
C3537225 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
Glucohemoglobin measurement
Item
hba1c (glycosylated haemoglobin a1c) between 7.5-10.0% by central laboratory analysis
boolean
C0202054 (UMLS CUI [1])
Body mass index
Item
bmi (body mass index) lesser than or equal to 45.0 kg/m2
boolean
C1305855 (UMLS CUI [1])
Subcutaneous Injections Quantity per day Able | Subcutaneous Injections Quantity per day Willing
Item
able and willing to take one subcutaneous injection every day
boolean
C0021499 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0439505 (UMLS CUI [1,3])
C0085732 (UMLS CUI [1,4])
C0021499 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0439505 (UMLS CUI [2,3])
C0600109 (UMLS CUI [2,4])
Plasma Glucose Measurement Self Able | Plasma Glucose Measurement Self Willing
Item
able and willing to perform mandatory smpg (self measured plasma glucose) measurements
boolean
C0202042 (UMLS CUI [1,1])
C0036588 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0202042 (UMLS CUI [2,1])
C0036588 (UMLS CUI [2,2])
C0600109 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Investigational New Drugs | Hypersensitivity Suspected Investigational New Drugs | Intolerance to Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Related | Hypersensitivity Suspected Pharmaceutical Preparations Related | Intolerance to Pharmaceutical Preparations Related
Item
known or suspected allergy or intolerance to any of the trial products or related products
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C1744706 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0013227 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C0750491 (UMLS CUI [5,2])
C0013227 (UMLS CUI [5,3])
C0439849 (UMLS CUI [5,4])
C1744706 (UMLS CUI [6,1])
C0013227 (UMLS CUI [6,2])
C0439849 (UMLS CUI [6,3])
Hypertension, severe
Item
severe hypertension
boolean
C4013784 (UMLS CUI [1])
Thiazolidinediones | GLP-1 Mimetics
Item
treatment with thiazolidinedione (tzd) or glp-1 (glucagon-like peptide-1) analogues within 2 months prior to trial start
boolean
C1257987 (UMLS CUI [1])
C3273809 (UMLS CUI [2])
Heart Disease
Item
cardiac disease, within the last 12 months
boolean
C0018799 (UMLS CUI [1])
Liver Dysfunction
Item
impaired hepatic function
boolean
C0086565 (UMLS CUI [1])
Renal Insufficiency
Item
impaired renal function
boolean
C1565489 (UMLS CUI [1])
Proliferative retinopathy Treatment required for | Macular retinal edema Treatment required for
Item
proliferative retinopathy or macular oedema requiring acute treatment
boolean
C0339467 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0271051 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
Childbearing Potential
Item
female of childbearing potential
boolean
C3831118 (UMLS CUI [1])
Alcohol abuse | Narcotic Abuse | DRUG ABUSE ILLICIT | Alcohol abuse Suspected | Narcotic Abuse Suspected | DRUG ABUSE ILLICIT Suspected
Item
known or suspected abuse of alcohol, narcotics or illicit substances
boolean
C0085762 (UMLS CUI [1])
C0524661 (UMLS CUI [2])
C0743253 (UMLS CUI [3])
C0085762 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0524661 (UMLS CUI [5,1])
C0750491 (UMLS CUI [5,2])
C0743253 (UMLS CUI [6,1])
C0750491 (UMLS CUI [6,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial